JP2015120685A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015120685A5 JP2015120685A5 JP2014236875A JP2014236875A JP2015120685A5 JP 2015120685 A5 JP2015120685 A5 JP 2015120685A5 JP 2014236875 A JP2014236875 A JP 2014236875A JP 2014236875 A JP2014236875 A JP 2014236875A JP 2015120685 A5 JP2015120685 A5 JP 2015120685A5
- Authority
- JP
- Japan
- Prior art keywords
- embolism
- thrombosis
- venous
- thromboembolic
- arterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000005189 Embolism Diseases 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 208000001435 Thromboembolism Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 230000009424 thromboembolic effect Effects 0.000 claims 8
- 208000007536 Thrombosis Diseases 0.000 claims 6
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 4
- 208000006011 Stroke Diseases 0.000 claims 4
- 206010047249 Venous thrombosis Diseases 0.000 claims 4
- 208000021328 arterial occlusion Diseases 0.000 claims 4
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims 4
- 230000000302 ischemic effect Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- DCBBOIFLGAMQFC-SFTDATJTSA-N 4-[[(2s,4s)-1-(4-carbamimidoylbenzoyl)-4-(4-methylsulfonylpiperazin-1-yl)pyrrolidine-2-carbonyl]amino]benzoic acid Chemical compound C1CN(S(=O)(=O)C)CCN1[C@@H]1CN(C(=O)C=2C=CC(=CC=2)C(N)=N)[C@H](C(=O)NC=2C=CC(=CC=2)C(O)=O)C1 DCBBOIFLGAMQFC-SFTDATJTSA-N 0.000 claims 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 206010002388 Angina unstable Diseases 0.000 claims 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 2
- 206010003178 Arterial thrombosis Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 2
- 206010008088 Cerebral artery embolism Diseases 0.000 claims 2
- 206010008092 Cerebral artery thrombosis Diseases 0.000 claims 2
- 206010008132 Cerebral thrombosis Diseases 0.000 claims 2
- 206010011091 Coronary artery thrombosis Diseases 0.000 claims 2
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 2
- 206010014513 Embolism arterial Diseases 0.000 claims 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 201000009454 Portal vein thrombosis Diseases 0.000 claims 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 2
- 208000006193 Pulmonary infarction Diseases 0.000 claims 2
- 206010063544 Renal embolism Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 208000007814 Unstable Angina Diseases 0.000 claims 2
- 230000007214 atherothrombosis Effects 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 230000001269 cardiogenic effect Effects 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 230000009852 coagulant defect Effects 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 208000002528 coronary thrombosis Diseases 0.000 claims 2
- 210000004351 coronary vessel Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 2
- 201000010849 intracranial embolism Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000003975 mesenteric artery Anatomy 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 230000003836 peripheral circulation Effects 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 230000007575 pulmonary infarction Effects 0.000 claims 2
- 210000001957 retinal vein Anatomy 0.000 claims 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 2
- 208000015891 sexual disease Diseases 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 201000005060 thrombophlebitis Diseases 0.000 claims 2
- 230000001052 transient effect Effects 0.000 claims 2
- 230000002861 ventricular Effects 0.000 claims 2
- 229940122036 Factor XIa inhibitor Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014236875A JP6337750B2 (ja) | 2013-11-22 | 2014-11-21 | 化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013241680 | 2013-11-22 | ||
| JP2013241680 | 2013-11-22 | ||
| JP2014236875A JP6337750B2 (ja) | 2013-11-22 | 2014-11-21 | 化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015120685A JP2015120685A (ja) | 2015-07-02 |
| JP2015120685A5 true JP2015120685A5 (OSRAM) | 2017-06-29 |
| JP6337750B2 JP6337750B2 (ja) | 2018-06-06 |
Family
ID=53532687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014236875A Expired - Fee Related JP6337750B2 (ja) | 2013-11-22 | 2014-11-21 | 化合物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6337750B2 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014160668A1 (en) | 2013-03-25 | 2014-10-02 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors |
| NO2760821T3 (OSRAM) | 2014-01-31 | 2018-03-10 | ||
| SG10201908467RA (en) | 2014-01-31 | 2019-10-30 | Bristol Myers Squibb Co | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors |
| WO2016036893A1 (en) | 2014-09-04 | 2016-03-10 | Bristol-Myers Squibb Company | Diamide macrocycles that are fxia inhibitors |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| EP3472151A4 (en) | 2016-06-21 | 2020-03-04 | Orion Ophthalmology LLC | CARBOCYCLIC PROLINAMIDE DERIVATIVES |
| WO2017222915A1 (en) | 2016-06-21 | 2017-12-28 | Inception 4, Inc. | Heterocyclic prolinamide derivatives |
| JP7210540B2 (ja) | 2017-08-04 | 2023-01-23 | 武田薬品工業株式会社 | 血漿カリクレインの阻害剤およびその使用 |
| JPWO2020059812A1 (ja) | 2018-09-20 | 2021-08-30 | 小野薬品工業株式会社 | ４−（｛（４ｓ）−１−（４−カルバムイミドイルベンゾイル）−４−［４−（メチルスルホニル）ピペラジン−１−イル］−ｌ−プロリル｝アミノ）安息香酸の新規塩およびその新規結晶形 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002037937A2 (en) * | 2000-11-07 | 2002-05-16 | Bristol-Myers Squibb Company | Acid derivatives useful as serine protease inhibitors |
| CN1809346A (zh) * | 2003-06-18 | 2006-07-26 | 默克专利股份公司 | 作为凝血因子xa和viia的抑制剂用于治疗形成血栓的1－[(4－乙炔基苯基) ]－2－[(苯基)]－吡咯烷－1,2－二酰胺衍生物 |
| JP5263686B2 (ja) * | 2006-05-16 | 2013-08-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換プロリンアミド、その製造及び薬物としての使用 |
| TW201011006A (en) * | 2008-06-16 | 2010-03-16 | Nuevolution As | IAP binding compounds |
| GB201209138D0 (en) * | 2012-05-24 | 2012-07-04 | Ono Pharmaceutical Co | Compounds |
-
2014
- 2014-11-21 JP JP2014236875A patent/JP6337750B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015120685A5 (OSRAM) | ||
| JP2015524443A5 (OSRAM) | ||
| RU2014152276A (ru) | Замещенные пирролидины в качестве ингибиторов фактора xia для лечения тромбоэмболических заболеваний | |
| JP2016510326A5 (OSRAM) | ||
| JP2010526103A5 (OSRAM) | ||
| JP2018538367A5 (OSRAM) | ||
| JP2014530240A5 (OSRAM) | ||
| JP2017222722A5 (OSRAM) | ||
| JP2016513714A5 (OSRAM) | ||
| RU2017124150A (ru) | Производное дигидроиндолизинона | |
| RU2017112747A (ru) | Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции | |
| JP2017517512A5 (OSRAM) | ||
| TW201613932A (en) | Organic compounds | |
| CR20220096A (es) | Proteínas de fusión terapéuticas | |
| JP2019519533A5 (OSRAM) | ||
| SA523441083B1 (ar) | أحماض بيرازولو بيبريدين كربوكسيليك تحمل بدائل | |
| JP2017505809A5 (OSRAM) | ||
| HK1246649A1 (zh) | 柠檬酸铁在治疗缺铁性贫血中的用途 | |
| JP2018522024A5 (OSRAM) | ||
| MY195760A (en) | Use of IDHP in Preparation of Drug or Health Product for Prevention and Treatment of Coronary Atherosclerosis Disease | |
| JP2016512243A5 (OSRAM) | ||
| JP2016069317A5 (ja) | 腎不全進行抑制剤、腎不全予防剤、尿毒症治療剤、インドキシル硫酸産生阻害剤、心血管系疾患予防剤、及び食品組成物 | |
| JP2018536620A5 (OSRAM) | ||
| JP2017509701A5 (OSRAM) | ||
| JP2016523943A5 (OSRAM) |